FLNA Stock Chart & Stats
$23.00
$0.00(0.00%)
―
--
Day’s Range― - ―
52-Week Range$16.30 - $86.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
$815.62M
Enterprise Value-$4.93
Total Cash (Recent Filing)$95.50M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.07
Next Earnings
Aug 05, 2026EPS Estimate
-3.94Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.96
Shares Outstanding48,307,896
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.33
Price to Sales (P/S)0.00
P/FCF Ratio-3.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
FLNA FAQ
What was Filana Therapeutics, Inc.’s price range in the past 12 months?
Filana Therapeutics, Inc. lowest stock price was $16.30 and its highest was $86.00 in the past 12 months.
What is Filana Therapeutics, Inc.’s market cap?
Filana Therapeutics, Inc.’s market cap is $815.62M.
When is Filana Therapeutics, Inc.’s upcoming earnings report date?
Filana Therapeutics, Inc.’s upcoming earnings report date is Aug 05, 2026 which is in 11 days.
How were Filana Therapeutics, Inc.’s earnings last quarter?
Filana Therapeutics, Inc. released its earnings results on May 07, 2026. The company reported -$3.677 earnings per share for the quarter, beating the consensus estimate of -$4.027 by $0.35.
Is Filana Therapeutics, Inc. overvalued?
According to Wall Street analysts Filana Therapeutics, Inc.’s price is currently Undervalued.
Does Filana Therapeutics, Inc. pay dividends?
Filana Therapeutics, Inc. does not currently pay dividends.
What is Filana Therapeutics, Inc.’s EPS estimate?
Filana Therapeutics, Inc.’s EPS estimate is -3.94.
How many shares outstanding does Filana Therapeutics, Inc. have?
Filana Therapeutics, Inc. has 48,307,896 shares outstanding.
What happened to Filana Therapeutics, Inc.’s price movement after its last earnings report?
Filana Therapeutics, Inc. reported an EPS of -$3.677 in its last earnings report, beating expectations of -$4.027. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Filana Therapeutics, Inc.?
Currently, no hedge funds are holding shares in MX:FLNA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Filana Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-65.48%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-23.11%
Trailing 12-Months
Company Description
Filana Therapeutics, Inc.
Filana Therapeutics, Inc. is a company dedicated to pioneering new pharmaceutical products and diagnostic technologies. A key area of its research is focused on creating potential treatments for Alzheimer's disease, including the investigational compounds PTI-125 and PTI-125Dx. Established by Remi Barbier in May 1998, the firm maintains its principal office in Austin, Texas.